Ambrosia Biosciences closed a $100 million Series B funding round on March 31, 2026, co-led by Blue Owl Healthcare Opportunities, Redmile Group, and Deep Track Capital14
The Boulder-based company develops orally bioavailable small molecule GLP-1 receptor agonist therapies as alternatives to injectable treatments for obesity and cardiometabolic disorders1
Funding will advance the lead oral GLP-1R agonist candidate (AMB-234) through IND-enabling studies into Phase 1 clinical trials1
The small-molecule therapy is designed to offer 24-hour coverage, low effective dosing, and better combinability compared to peptide-based treatments34
Existing investors BVF Partners and Boulder Ventures participated alongside new investors Janus Henderson Investors and Samsara BioCapital14
The anti-obesity drugs market is projected to grow from $22.5 billion in 2026 to $196 billion by 2036 at a 24.2% compound annual growth rate1
Ambrosia's pipeline also includes GIPR antagonist and amylin agonist programs targeting Class B GPCRs1
The company operates from a 24,000 square foot integrated lab facility on the former Array BioPharma campus in Boulder, utilizing cryo-EM structural biology and AI-powered drug design1
Sources:
1. https://www.tamradar.com/funding-rounds/ambrosia-series-b-100m
3. https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-26
4. https://www.fiercebiotech.com/biotech/ambrosia-scores-100m-series-b-support-next-gen-glp-1